Ocular Patents (Class 424/427)
-
Patent number: 10517759Abstract: The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.Type: GrantFiled: March 12, 2014Date of Patent: December 31, 2019Assignee: GLAUKOS CORPORATIONInventors: Douglas Daniel Crimaldi, Charles Raymond Kalina, Jr.
-
Patent number: 10500281Abstract: What is disclosed is a semi-solid controlled release pharmaceutical composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution, a method of using the pharmaceutical composition to treat, and a method of making the pharmaceutical composition.Type: GrantFiled: August 28, 2015Date of Patent: December 10, 2019Assignee: Mira Pharma CorporationInventors: Hui Rong Shen, Na Gan
-
Patent number: 10500163Abstract: A sterile pharmaceutical dosage form which comprises an ester capped lactide polymer, glycolide polymer or a lactide-glycolide copolymer hypercompressed with an active pharmaceutical ingredient wherein said sterile pharmaceutical dosage form has been sterilized with an electron beam and a method of preparing said sterile pharmaceutical dosage form.Type: GrantFiled: July 10, 2018Date of Patent: December 10, 2019Assignee: SUSTAINED NANO SYSTEMS LLCInventors: Barry M. Libin, Jeffrey M. Liebmann, Weiliam Chen
-
Patent number: 10478531Abstract: This document provides methods and materials for treating a mammal (e.g., a human) having one or more stenotic blood vessels. For example, amnion coated balloons that can be used in balloon angioplasty are provided.Type: GrantFiled: September 19, 2017Date of Patent: November 19, 2019Inventor: Gary M. Petrucci
-
Patent number: 10478527Abstract: This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.Type: GrantFiled: September 5, 2016Date of Patent: November 19, 2019Assignee: University of the Witwatersrand, JohannesburgInventors: Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit, Poornima Ramburrun
-
Patent number: 10449086Abstract: A conjunctival cover including an annular generally curved shell having a conjunctival portion structured to conform to and overly at least part of the conjunctiva of an eye. The annular generally partially spherical shell defines a generally central opening. The central opening is sized to leave a cornea of the eye substantially or partially uncovered when the conjunctival cover is applied to the eye.Type: GrantFiled: May 30, 2017Date of Patent: October 22, 2019Inventor: Vance M. Thompson
-
Patent number: 10441747Abstract: Methods and kits for delivering pharmaceutical agents to an adventitia and other regions outside an external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of a pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent. In one example, catheters are used to deliver dexamethasone and other anti-inflammatory agents to a peripheral vasculature and other vasculature to treat peripheral vascular disease and other conditions.Type: GrantFiled: January 26, 2015Date of Patent: October 15, 2019Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 10420724Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.Type: GrantFiled: November 23, 2016Date of Patent: September 24, 2019Assignee: Incept, LLCInventors: Peter Jarrett, Michael J. McGrath, Timothy S. Jarrett, Rami El-Hayek, Andrew C. Vanslette, Courtney A. Rosales, Charles D. Blizzard, Amarpreet S. Sawhney
-
Patent number: 10406028Abstract: A surgical tool for inserting a spile or plug into the punctal opening of a meatus such as a lacrimo-nasal canaliculus comprises an oblong, hollowed member shaped and dimensioned to be conveniently manipulated with one hand and having at one end a punctal opening and meatus-dilating shaft and, at the opposite end, a plug inserter. The dilating shaft has a cross-diameter substantially equal to the cross-diameter of the plug and is terminated by a conical spike. The inserter comprises a tip extending axially from the member and having, at its distal end, a cup whose internal geometry is commensurate with a cap at the proximal end of the plug. A penetration-resisting bearing surface is provided by the cup rim. A notch through the cup wall improves visualization of the plug during insertion. A steel wire running through the inserter has its distal end inserted into the cap of the plug.Type: GrantFiled: March 20, 2015Date of Patent: September 10, 2019Inventor: Bruce B. Becker
-
Patent number: 10408974Abstract: Disclosed are high refractive index, hydrophobic, acrylic materials. These materials have both high refractive index and a high Abbe number. This combination means the materials have a low refractive index dispersion and thus are especially suitable for use as intraocular lens materials. The materials are also suitable for use in other implantable ophthalmic devices, such as keratoprostheses, corneal rings, corneal implants, and corneal inlays.Type: GrantFiled: June 1, 2018Date of Patent: September 10, 2019Assignee: Novartis AGInventor: Douglas Schlueter
-
Patent number: 10406102Abstract: A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50,000 to 350,000 psi.Type: GrantFiled: July 10, 2018Date of Patent: September 10, 2019Assignee: SUSTAINED NANO SYSTEMS LLCInventors: Barry M. Libin, Jeffrey M. Liebmann, Weiliam Chen
-
Patent number: 10398763Abstract: Methods are provided for treating astigmatism in an eye of a patient. An axis of greater curvature of the eye is determined. A stiffening process is applied to a cornea of the eye in a pattern defined from the axis of greater curvature of the eye.Type: GrantFiled: January 28, 2014Date of Patent: September 3, 2019Assignee: THE CLEVELAND CLINIC FOUNDATIONInventors: William J. Dupps, Ibrahim Seven
-
Patent number: 10398755Abstract: Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.Type: GrantFiled: December 16, 2015Date of Patent: September 3, 2019Assignee: University of Southern CaliforniaInventors: M. Elizabeth Fini, Shinwu Jeong
-
Patent number: 10350161Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.Type: GrantFiled: October 14, 2014Date of Patent: July 16, 2019Assignee: PHARMATHEN S.A.Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Andreas Kakouris, George Gotzamanis
-
Patent number: 10336896Abstract: A method of forming a hybrid physically and chemically cross-linked double-network hydrogel with highly recoverable and mechanical properties in a single-pot synthesis is provided. The method comprises the steps of combining the hydrogel precursor reactants into a single pot. The hydrogel precursor reactants include water; a polysaccharide; a methacrylate monomer; an ultraviolet initiator; and a chemical crosslinker. Next the hydrogel precursor reactants are heated to a temperature higher than the melting point of the polysaccharide and this temperature is retained until the polysaccharide is in a sol state. Then the single-pot is cooled to a temperature lower than the gelation point of the polysaccharide and this temperature is retained to form a first network. Thereafter, photo-initiated polymerization of the methacrylate monomer occurs via the ultraviolet initiator to form the second network.Type: GrantFiled: April 23, 2014Date of Patent: July 2, 2019Assignee: The University of AkronInventors: Jie Zheng, Qiang Chen, Chao Zhao
-
Patent number: 10314780Abstract: The invention refers to a drippable ophthalmic gel, said gel having composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of >0.2% by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10% by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.Type: GrantFiled: June 8, 2016Date of Patent: June 11, 2019Assignee: MEDPROJECT PHARMA-ENTWICKLUNGS-UND VERTRIEBSGESELLSCHAFT MBHInventors: Heinz Polzer, Pierre-Paul Elena, Jürgen Senge
-
Patent number: 10314924Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.Type: GrantFiled: July 17, 2015Date of Patent: June 11, 2019Assignees: Massachusetts Eye & Ear Infirmary, UCL Business PLC, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
-
Patent number: 10315019Abstract: Implantable drug delivery devices include a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, and a drug contained in the drug reservoir lumen, wherein the first wall structure is impermeable to the drug and the second wall structure is permeable to the drug. Methods of providing controlled release of drug to a patient include deploying a drug delivery device in the patient releasing a drug from the drug reservoir lumen via diffusion through the second wall structure.Type: GrantFiled: March 17, 2014Date of Patent: June 11, 2019Assignee: TARIS BIOMEDICAL LLCInventors: Heejin Lee, Karen Daniel, Matthew Sansone
-
Patent number: 10307292Abstract: Provided is a device for use in controlling the liquid outflow from the anterior chamber of the eye, methods of draining aqueous humor from the anterior chamber to the intra-orbital space using the device, methods for controlling the liquid outflow from the anterior chamber of the eye and further surgical methods for implanting the presently described device.Type: GrantFiled: July 18, 2012Date of Patent: June 4, 2019Assignee: MOR RESEARCH APPLICATIONS LTDInventor: Gilad Litvin
-
Patent number: 10300114Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.Type: GrantFiled: July 1, 2014Date of Patent: May 28, 2019Assignee: EyePoint Pharmaceuticals US, Inc.Inventors: Hong Guo, Jianbing Chen, Dongling Su, Paul Ashton
-
Patent number: 10278920Abstract: A drug delivery implant and a method of using the same are disclosed herein. In one or more embodiments, the method includes forming a pocket in the cornea of the eye to gain access to tissue surrounding the pocket; applying a photosensitizer inside the pocket so the photosensitizer permeates at least a portion of the tissue surrounding the pocket and facilitates cross-linking of the tissue surrounding the pocket; irradiating the cornea to activate cross-linkers in the portion of the tissue surrounding the pocket, and thereby stiffen a wall of the pocket and kill cells in the portion of the tissue surrounding the pocket; and before or after the portion of the tissue surrounding the pocket has been stiffened and is devoid of cellular elements by the activation of the cross-linkers, inserting a corneal drug delivery implant into the pocket configured to release one or more medications into the eye.Type: GrantFiled: November 17, 2017Date of Patent: May 7, 2019Inventor: Gholam A. Peyman
-
Patent number: 10231830Abstract: A prosthetic heart valve provided herein can include a kidney capsule tissue leaflet. In some cases, a prosthetic heart valve can include a plurality of leaflets secured together and retained within the expandable tubular member. The kidney capsule tissue can be obtained from a farm animal, such as a cow, pig, horse, goat, or sheep. In some cases, the kidney capsule tissue can be tensioned (e.g., bi-axially tensioned) and/or chemically cross-linked.Type: GrantFiled: November 1, 2016Date of Patent: March 19, 2019Assignee: Boston Scientific Scimed, Inc.Inventors: Lynne E. Swanson, Crystal Marie Anderson-Cunanan, Katherine Cora Fazackerley, Philip D. Crompton
-
Patent number: 10231926Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.Type: GrantFiled: November 14, 2016Date of Patent: March 19, 2019Assignee: Allergan, Inc.Inventors: Jane-Guo Shiah, Chetan Pujara
-
Patent number: 10226419Abstract: Pharmacologically active implants, in particular subcutaneous implants, intrauterine devices, and intravaginal rings, are provided herein. Methods for forming an active ingredient-containing core are described. Methods for laminating an active ingredient-containing core to form a rate-controlling sheath are also described.Type: GrantFiled: September 8, 2015Date of Patent: March 12, 2019Assignee: PROMED PHARMA, LLCInventors: James H. Arps, Matthew Petersen
-
Patent number: 10213405Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.Type: GrantFiled: May 3, 2017Date of Patent: February 26, 2019Assignee: ALLERGAN, INC.Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
-
Patent number: 10206813Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.Type: GrantFiled: March 7, 2014Date of Patent: February 19, 2019Assignee: Dose Medical CorporationInventors: David S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
-
Patent number: 10195212Abstract: Particles encapsulating a glucocorticoid such as dexamethasone sodium phosphate (DSP) into a matrix such as biodegradable poly(lactic-coglycolic acid) (PLGA) which is densely coated with hydrophilic polymer such as PEG or PLURONIC® F127, exhibit sustained release of DSP for up to 7 days in vitro. These nanoparticles can be used to prevent corneal graft rejection or corneal neovascularization.Type: GrantFiled: August 3, 2015Date of Patent: February 5, 2019Assignee: The Johns Hopkins UniversityInventors: Justin Scot Hanes, Qing Pan, Qingguo Xu, Nicholas J. Boylan, Walter J. Stark, Bing Wang, Lixia Luo
-
Patent number: 10188853Abstract: The present invention is a flexible circuit electrode array with a polymer base layer, metal traces deposited on the polymer base layer, including electrodes suitable to stimulate neural tissue, a polymer top layer deposited on the polymer base layer and the metal traces, and a soft polymer filling a void through both the polymer base layer and polymer top layer, the soft polymer forming drum stress relief around an attachment point.Type: GrantFiled: March 7, 2008Date of Patent: January 29, 2019Assignee: Second Sight Medical Products, Inc.Inventors: Rajat Agrawal, Robert J. Greenberg, Mark S. Humayun, James Singleton Little, Brian V. Mech, Jordan Matthew Neysmith, Neil Hamilton Talbot, Dao Min Zhou
-
Patent number: 10174006Abstract: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).Type: GrantFiled: May 30, 2014Date of Patent: January 8, 2019Assignee: NOVARTIS AGInventors: Malay Ghosh, Christopher Michael Adams, Stephanie Kay Dodd, Stephen Hedrick Poor
-
Patent number: 10143670Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.Type: GrantFiled: October 18, 2017Date of Patent: December 4, 2018Inventor: Lanny Leo Johnson
-
Patent number: 10143703Abstract: Methods of treating ocular neovascularization, e.g., associated with wet agerelated macular degeneration (AMD), using activators of AMP-activated protein kinase (AMPK) and/or of Phosphatase and tensin homolog deleted on chromosome 10 (PTEN).Type: GrantFiled: January 2, 2015Date of Patent: December 4, 2018Assignee: Massachusetts Eye and Ear InfirmaryInventors: Demetrios Vavvas, Joan W. Miller, Kimio Takeuchi
-
Patent number: 10137199Abstract: The invention provides methods, compositions and kits relating to hyaluronan based matrices using oxidized glutathione as a crosslinking agent.Type: GrantFiled: May 12, 2014Date of Patent: November 27, 2018Assignee: BioTime, Inc.Inventors: Thomas Zarembinski, Isaac Erickson, Nathaniel Doty
-
Patent number: 10105465Abstract: The present invention provides a biodegradable medical adhesive or a sealant composition containing an oxidized glycosaminoglycan and a polyamine. The composition of the present invention exhibits improved effects in biodegradation, coating property, gelation time, hemostatic capacity, adhesive force, moisture absorptive capacity and the like, and thus can be applied to various medical uses in which a medical adhesive or sealant can be used, such as biotissue adhesion, filling, coating, adhesion prevention, wound covering, leakage prevention and hemostasis.Type: GrantFiled: December 12, 2014Date of Patent: October 23, 2018Assignee: UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTERInventors: Eunhye Lee, Jin Hee Maeng, Keun Su Kim, Don Haeng Lee, Young Hwan Park
-
Patent number: 10092506Abstract: The present invention relates to a therapeutic agent formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises further to the therapeutic agent, at least one amphiphilic lipid and at least one solubilizing lipid, and in which the aqueous phase comprises at least one polyalkoxylated cosurfactant. The invention also relates to a preparation method and use of this formulation.Type: GrantFiled: August 14, 2009Date of Patent: October 9, 2018Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Veronique Mourier-Robert, Jerome Bibette, Mathieu Goutayer, Fabrice Navarro y Garcia, Isabelle Texier-Nogues
-
Patent number: 10010502Abstract: A non-degradable topical ocular drug delivery device includes about 0.001% to about 10% w/w of at least one myopia-suppressing agent complexed with an immobile acid within a crosslinked polymer matrix. The cross-linked polymer matrix is configured to deliver the least one myopia-suppressing agent over an extended period of time at a concentration and rate that controls myopia progression while preserving pupillary function and accommodation.Type: GrantFiled: May 19, 2016Date of Patent: July 3, 2018Assignee: AMORPHEX THERAPEUTICS LLCInventors: Charles D. Leahy, Edward J. Ellis
-
Patent number: 9999708Abstract: The present invention relates to a process for manufacturing an object made of biocompatible hydrogel by molding a polymer solution in a mold made of a particular material, said process comprising the following steps: (i) preparation of a polymer solution by dissolving a copolymer of acrylonitrile and of an olefinically unsaturated co-monomer bearing anionic groups in an aprotic solvent, optionally in the presence of a nonsolvent, (ii) shaping and the start of gelation of the polymer solution obtained at the end of step (i) in a mold consisting of a material containing said nonsolvent or of a material permeable to said nonsolvent, (iii) immersion of the object undergoing gelation resulting from step (ii) in a nonsolvent. The present invention also relates to the objects made of biocompatible hydrogel resulting from this process such as, for example, intracorneal lenses (or lenticules) implantable in the cornea or any other implants usable in ophthalmology.Type: GrantFiled: June 14, 2013Date of Patent: June 19, 2018Inventor: Laurent Laroche
-
Patent number: 9968420Abstract: A tooth protection device that is operable to provide impact protection and thermal protection for a damaged tooth within a user's mouth. The tooth protection device includes a base layer that is rectangular in shape and is manufactured from a malleable gum resin. The base layer further has an internal thermal layer that is operable to provide a thermal barrier so as to inhibit the change of temperature proximate the tooth. The base layer further includes a medicament impregnated therein that is operable to provide pain relief to the area. The medicament comprises a natural medicament or a synthetic medicament. The base layer extends from the gum line on a first side of a tooth, across the top of the tooth and reaching the gum line on the second side of the tooth.Type: GrantFiled: December 4, 2015Date of Patent: May 15, 2018Inventor: Beverly Maston
-
Patent number: 9962334Abstract: The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material.Type: GrantFiled: July 24, 2017Date of Patent: May 8, 2018Assignee: Novartis AGInventors: Brett E. Thomes, Stephen J. Van Noy, Chi-Chun Tsai
-
Patent number: 9949942Abstract: The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).Type: GrantFiled: May 8, 2009Date of Patent: April 24, 2018Assignee: Mati Therapeutics Inc.Inventor: Zuhal Butuner
-
Patent number: 9937129Abstract: This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.Type: GrantFiled: January 22, 2016Date of Patent: April 10, 2018Assignee: The Regents of the University of CaliforniaInventors: William R. Freeman, Michael J. Sailor, Lingyun Cheng
-
Patent number: 9937073Abstract: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.Type: GrantFiled: January 20, 2015Date of Patent: April 10, 2018Assignee: ForSight Vision5, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Cary J. Reich, K. Angela Macfarlane, Janelle Chang, Stephen Boyd, David Sierra, Jose D. Alejandro, Douglas Sutton, Alexander J. Gould
-
Patent number: 9925293Abstract: A solution for treating contact lens is provided. The solution includes about 0.01-1.0 parts by weight (pbw) of a polymer having phosphorylcholine groups, about 0.01-1 pbw of an inorganic salt, and about 100 pbw of water. The polymer has a number-average molecular weight of about 4,000 to about 1,000,000 daltons and has a structure of formula (I): wherein, in formula (I), m is a positive integer, n is zero or a positive integer, and R is C2-C12 alkyl group or C2-C12 hydroxyalkyl group. When n is a positive integer, m/n is greater than 1.Type: GrantFiled: September 5, 2016Date of Patent: March 27, 2018Assignee: PEGAVISION CORPORATIONInventors: Han-Yi Chang, Ya-Hsuan Liao, Shu-Chen Lu, Ya-Hui Chang, Yu-Chin Lai
-
Patent number: 9895535Abstract: The application relates to a hearing assistance system (a method and its use) for processing an input signal representative of sound according to a user's needs, the hearing assistance system comprising an implanted part adapted for being at least partially implanted in a user's head and comprising a sensing unit capable of measuring an endocochlear potential at one or more positions along the length of the cochlear partition. The hearing assistance system further comprises a decoder configured to receive said endocochlear potentials or signals derived therefrom and to transform the received signals into signals appropriately conditioned for use as control inputs to the signal processing unit, and wherein the signal processing unit is configured to process the electric input signal in dependence of said control inputs from said decoder. Thereby the processing of the audio signal of a hearing assistance device can be automatically adapted over time.Type: GrantFiled: August 6, 2015Date of Patent: February 20, 2018Assignee: Oticon A/SInventor: Graham Naylor
-
Patent number: 9873736Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.Type: GrantFiled: August 18, 2014Date of Patent: January 23, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Lutz Asmus, Michael Möller, Robert Gurny, John P. A. Grimshaw
-
Patent number: 9855337Abstract: Biomaterials are disclosed having unique properties that make it a useful material in adhesives, local drug delivery applications and as filler or bulking material. The biomaterials are strong, safe and easily used as a surgical adhesive. Treated chitosan, modified chitosan or modified and treated chitosan compositions are disclosed displaying strengths suitable for general surgical applications. The materials can be used as a drug delivery vehicle which allows for the localization of the delivered drug as well as a programmable tether which allows for the release of the drug on a timed basis or in response to a physiological state such as the release of proteolytic enzymes. The materials of this invention can also be modified and treated to optimize the retention of water, thereby serving as a useful filler or bulking material.Type: GrantFiled: January 31, 2008Date of Patent: January 2, 2018Assignee: Alumend, LLCInventors: Ronald E. Utecht, Kaia L. Kloster, Therese M. Downey, Barbara R. Haberer
-
Patent number: 9827191Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: GrantFiled: November 2, 2013Date of Patent: November 28, 2017Assignee: The Johns Hopkins UniversityInventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
-
Patent number: 9808420Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.Type: GrantFiled: December 22, 2015Date of Patent: November 7, 2017Assignee: Novaer Holdings, INC.Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
-
Patent number: 9795562Abstract: A method for stabilizing a poorly water-soluble drug-containing amphiphilic block copolymer micelle composition via simplified steps in short time is described. Also described is a stabilized poorly water-soluble drug-containing amphiphilic block copolymer micelle composition having improved stability.Type: GrantFiled: May 20, 2015Date of Patent: October 24, 2017Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATIONInventors: Sa-Won Lee, Min-Hyo Seo
-
Patent number: 9788999Abstract: Disclosed are devices and methods for treatment of eye disease such as glaucoma. Implants are described herein that create a flow field, such as between the anterior chamber and either the supraciliary space or suprachoroidal space. In addition, the implant can be treated with one or more treatments, including plasma treatments, for creating a variety of surface features and characteristics. Some of the surface features and characteristics can assist in controlling tissue responses to the implanted implant, including promoting or preventing tissue proliferation.Type: GrantFiled: May 21, 2014Date of Patent: October 17, 2017Inventor: Michael Schaller
-
Patent number: 9791721Abstract: An ophthalmic lens includes a matrix and a natural yellow dye dispersed in the matrix. The natural yellow dye includes at least one of lutein and zeaxanthin.Type: GrantFiled: October 9, 2015Date of Patent: October 17, 2017Assignee: HON HAI PRECISION INDUSTRY CO., LTD.Inventor: Hsiu-Wen Chien